Publication details

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Authors	GIRALT S. STADTMAUER EA. HAROUSSEAU JL. PALUMBO A. BESINGER W. COMENZO RL. KUMAR S. MUNSHI NC. DISPENZIERI A. KYLE R. MERLINI G. SAN MIGUEL J. LUDWIG H. HÁJEK Roman JAGANNATH S. BLADE J. LONIAL S. DIMOPOULOS MA. EINSELE H. BARLOGIE B. ANDERSON KC. GERTZ M. ATTAL M. TOSI P. SONNEVELD P. BOCCADORO M. MORGAN G. SEZER O. MATEOS MV. CAVO M. JOSHUA D. TURESSON I. CHEN W. SHIMIZU K. POWLES R. RICHARDSON PG. NIESVIZKY R. RAJKUMAR SV. DURIE BGM.
Year of publication	2009
Type	Article in Periodical
Magazine / Source	Leukemia
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	multiple myeloma; stem cell; plerixafor
Description	Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.